Branded Weight Loss Shift Surges: Platform Scales Global Footprint (HIMS Q1 2026 Earnings Call)

By Dr. Graph | Updated on May 31, 2026 | earnings

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Hims & Hers Health, Inc. is leveraging its record subscriber growth and Novo Nordisk Wegovy partnership to expand its addressable weight loss market and accelerate global platform scale.

Strategic Pivot and Branded Focus Fuel Subscriber Expansion

Hims & Hers Health delivered a strong start to the fiscal year, driven by a transformational portfolio shift and rapid global market expansion. The company reported that first-quarter consolidated revenue rose 4% year-over-year to $608 million. This growth was supported by accelerating customer acquisitions, bringing total platform subscribers to nearly 2.6 million to exceed initial targets.

Affirmed Long-Term Ambitions Lift Full-Year Financial Guidance

Following early success from its weight loss transition, management raised its full-year guidance to reflect scaling global capabilities and platform demand. For the full fiscal year, Hims & Hers now expects total revenue in the range of $2.8 billion to $3.0 billion. The company projects full-year adjusted EBITDA between $275 million and $350 million. CEO Andrew Dudum reinforced long-term confidence in the company's 2030 revenue target of at least $6.5 billion.

Partnership Shipments and Strategic M&A Accelerate Global Footprint

Segment results highlighted rapid adoption of direct-access branded treatments following a strategic shift in the weight loss specialty. Within six weeks of collaborating with Novo Nordisk to offer Wegovy products, Hims & Hers fulfilled more than 125,000 shipments to subscribers. This robust domestic volume was complemented by the international acquisitions of ZAVA and Livewell. Additionally, the planned acquisition of Eucalyptus in the second half of the year will establish category leadership across multiple global markets.

Restructuring Asset Obsolescence and Marketing Gains Highlight Q&A Insights

During the analyst Q&A session, management discussed strategic investments, peptide safety, and customer acquisition costs. To focus on branded medications, the company retired its compounding GLP-1 supply chain, incurring approximately $33 million in nonrecurring restructuring costs. CFO Yemi Okupe noted that strong organic cross-sell and customer retention drove marketing expenses down to 36% of revenue, a sequential improvement of 3 percentage points. Addressing questions on peptide therapies, CEO Andrew Dudum stated, "we won't launch access to peptides until we meet these very high standards that we believe everyone should be meeting."

Frequently Asked Questions

Why did Hims & Hers make a strategic shift to branded weight loss products in March?

The strategic shift was designed to prioritize branded Wegovy pill and pen options under a Novo Nordisk collaboration, expanding the addressable market and attracting a highly engaged customer base to the platform at scale.

What restructuring costs were incurred due to the weight loss strategic pivot?

Hims & Hers incurred approximately $33 million in nonrecurring restructuring costs. This primarily consisted of a $28 million write-down for compounded GLP-1 supply chain assets facing risk of obsolescence, which compressed gross margins by roughly 5 points.

What did the company disclose about its upcoming Eucalyptus acquisition?

The acquisition of Eucalyptus, expected to close in the second half of the year, will extend Hims & Hers' consumer health leadership across Australia, the U.K., Germany, Japan, and Canada. Hims expects to make a $240 million payment at closing, with earn-out structures extending through 2029.

How did customer acquisition efficiency perform during the first quarter?

Customer acquisition efficiency improved, with marketing expenses as a percentage of revenue declining to 36% (a sequential and year-over-year improvement of 3 percentage points). This gain was driven by stronger customer retention and increased organic cross-selling on the platform.